Nuvo Research Announces New Listing of Synera® Patent in FDA Orange Book
News Dec 27, 2012
Nuvo Research Inc. has announced that the United States Patent Office has granted the reinstatement of Patent No. 6,465,709 related to Synera® Patch (Synera Patent).
Nuvo has listed the Synera Patent in the U.S. Food and Drug Administration's (FDA) Orange Book.
The Orange Book listing requires an Abbreviated New Drug Application (ANDA) applicant seeking FDA approval for a generic version of Synera prior to expiration of the patent to notify Nuvo of its ANDA filing before it can obtain FDA approval.
"We are very pleased that we have received additional patent protection for Synera Patch in the U.S.," said Tina Loucaides, Nuvo's Vice-President and General Counsel.
Loucaides continued, "The listing of this patent in the FDA Orange Book provides us with significantly more years of protection and will allow us to better explore expanded indications for this unique topical local anesthetic patch."
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE